Rifaximin Market, By Indication (Hepatic Encephalopathy (HE), Irritable Bowel Syndrome with Diarrhea (IBS-D), Traveler’s Diarrhea, Small Intestinal Bacterial Overgrowth (SIBO), Inflammatory Bowel Disease–Associated Diarrhea (IBD-D), Clostridioides difficile–Associated Diarrhea (adjunct use), and Other Gastrointestinal Infections), By Dosage Form (Tablet and Oral Suspension), By Strength (200 mg, 400 mg, and 550 mg), By Patient Group (Adult, Geriatric, and Pediatric), By End User (Hospitals, Gastroenterology Clinics, Ambulatory Surgical Centers, Academic and Research Institutes, and Home Healthcare Providers), By Manufacturer Category ( Branded and Generic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) , By Geography ( North America, Latin America, Europe, Asia Pacific, Middle East, Africa)